<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2392">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130021</url>
  </required_header>
  <id_info>
    <org_study_id>MAX-40279-005</org_study_id>
    <nct_id>NCT05130021</nct_id>
  </id_info>
  <brief_title>A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maxinovel Pty., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maxinovel Pty., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This include two parts, part 1 is a dose optimizing study and part 2 is a randomized,&#xD;
      controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a study of Max-40279-01 in patients with advanced colorectal cancer. This study&#xD;
      include two Parts, the Part 1 will assess the safety and efficacy of the preset two dose&#xD;
      level of Max-40279-01, and recommend a dose level of Max-40279-01 for stage 2. The part 2 is&#xD;
      a randomized, controlled study ,and designed to compare the efficacy and safety of&#xD;
      max-40279-01 to regorafenib or best support care(BSC) in pretreated advanced colorectal&#xD;
      cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2022</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR)[Part 1]</measure>
    <time_frame>Through study Part 1 completion, an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>progress free survival(PFS)[Part 2]</measure>
    <time_frame>Through study Part 1 completion, an average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Maximum plasma drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Area under the time-concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 months (anticipated)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by incidence and severity of adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1;50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1;70mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2;MAX-40279-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2;regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAX-40279-01</intervention_name>
    <description>MAX-40279-01 50mg/70mg</description>
    <arm_group_label>Part 1;50mg</arm_group_label>
    <arm_group_label>Part 1;70mg</arm_group_label>
    <arm_group_label>Part 2;MAX-40279-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <description>regorafenib</description>
    <arm_group_label>Part 2;regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and/or females over age 18&#xD;
&#xD;
          2. Histologically and/or cytologically documented local advanced or metastatic colorectal&#xD;
             adenocarcinoma.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          4. Expected survival &gt;3 months.&#xD;
&#xD;
          5. previously treated with standard, approved therapies, including two lines of&#xD;
             chemotherapy (fluoropyrimidine,oxaliplatin and irinotecan based), a biological VEGF&#xD;
             inhibitor, and, if RAS wild-type, an EGFR inhibitor. Patients with MSI-H/MMR-deficient&#xD;
             tumors also must have received an immune checkpoint inhibitor, if available and&#xD;
             approved. In addition, patients with BRAF mutant tumors must also have received a BRAF&#xD;
             inhibitor, if available and approved.&#xD;
&#xD;
          6. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known uncontrolled or symptomatic central nervous system metastatic disease.&#xD;
&#xD;
          2. Adverse events (with exception of alopecia, peripheral sensory neuropathy grade â‰¤ 2&#xD;
             and those listed in specific exclusion criteria) from any prior anticancer therapy of&#xD;
             grade &gt;1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.3.0) at&#xD;
             the time of randomization.&#xD;
&#xD;
          3. Inadequate organ or bone marrow function.&#xD;
&#xD;
          4. Medical history of difficulty swallowing, malabsorption or other chronic&#xD;
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption&#xD;
             of the tested product.&#xD;
&#xD;
          5. Pregnant or breast-feeding woman.&#xD;
&#xD;
          6. Known allergies, hypersensitivity, or intolerance to Max-40279-01 the excipients of&#xD;
             these treatments The above information was not intended to contain all considerations&#xD;
             relevant to a participant's potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanying Bao, MD,Ph.D</last_name>
    <phone>+86-021-51370693</phone>
    <email>hybao@maxinovel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanhong Y Deng, Dr</last_name>
    <phone>+8613925106525</phone>
    <email>13925106525@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanhong Deng, Dr</last_name>
      <phone>+86 13925106525</phone>
      <email>13925106525@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>pretreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

